DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses t...

Full description

Saved in:
Bibliographic Details
Main Authors LEE, Kyeong, BAN, Hyun-Seung, KIM, Bo-Kyung, WON, Mi Sun, KIM, Min Kyoung
Format Patent
LanguageEnglish
French
Korean
Published 29.07.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to: a disubstituted adamantyl derivative or a pharmaceutically acceptable salt thereof, and an anticancer pharmaceutical composition and a kit containing same as an active ingredient. The disubstituted adamantyl derivative according to the present invention suppresses the growth of cancer cells by targeting mitochondria ETC complex I and damaging the metabolism of cancer cells, and thus can be useful as an anticancer pharmaceutical composition that is a powerful therapeutic agent for cancer dependent on oxidative phosphorylation for producing ATP. La présente invention concerne : un dérivé d'adamantyle disubstitué ou son sel pharmaceutiquement acceptable, ainsi qu'une composition pharmaceutique anticancéreuse et un kit le contenant comme principe actif. Le dérivé d'adamantyle disubstitué selon la présente invention empêche la croissance des cellules cancéreuses par ciblage du complexe I des mitochondries ETC et par la destruction du métabolisme des cellules cancéreuses, et peut ainsi être utile en tant que composition pharmaceutique anticancéreuse qui est un agent thérapeutique puissant contre le cancer dépendant de la phosphorylation oxydative afin de produire de l'ATP. 본 발명은 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 항암용 약학적 조성물과 키트에 관한 것으로, 본 발명에 따른 이치환 아다만틸 유도체는 미토콘드리아 ETC 복합체 I을 표적화하고 암 세포 대사를 손상시킴으로써 암 세포의 성장을 억제하는바, ATP 생성을 위한 산화적 인산화에 의존하는 암에 대한 강력한 치료제로서 항암용 약학적 조성물로 유용하게 사용될 수 있다.
Bibliography:Application Number: WO2020KR16110